| Literature DB >> 31558077 |
Ching-Yi Lee1,2, Yuan-Chuan Chen3, Ying-Piao Wang4,5, Shiu-Jau Chen1,2.
Abstract
Entities:
Keywords: Pituitary adenoma; cerebrospinal fluid (CSF); endoscopic endonasal transsphenoidal approach (EETA); magnetic resonance imaging (MRI); transcranial approach; transsphenoidal approach
Mesh:
Year: 2019 PMID: 31558077 PMCID: PMC6862880 DOI: 10.1177/0300060519875857
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Figure 1.A patient with a nonfunctional pituitary macroadenoma underwent adenomectomy by extracapsular dissection. (a) Preoperative brain MRI (the signal T1 is sagittal with contrast): The tumor was 4 cm in diameter with suprasellar extension (yellow arrow). (b) Postoperative MRI: No residual tumor was present at the 1-year follow-up (yellow arrow). (c) After central debulking, the tumor was dissected between the capsule (black arrow) and cavernous sinus (asterisk). (d) Because of high-flow cerebrospinal fluid leakage after tumor removal, a nasoseptal flap (black arrow) was harvested to cover the arachnoid and dura defect. Abbreviation: MRI, magnetic resonance imaging.
Demographics and surgical outcomes of patients.
Pituitary adenoma | ||||
|---|---|---|---|---|
| PatientVariable | Total (n = 38) | Functional (n = 12) | Nonfunctional (n = 26) | |
|
| ||||
| Sex | 0.161 | |||
| Female | 21 | 9 | 12 | |
| Male | 17 | 3 | 14 | |
| Age (years) | 54.3 ± 11.2 | 48.4 ± 9.7 | 57.1 ± 10.9 | 0.025 |
| Tumor size (cm) | 2.2 ± 0.9 | 1.6 ± 1.0 | 2.5 ± 0.8 | 0.009 |
| Tumor type | <0.001 | |||
| Microadenoma | 6 | 6 | 0 | |
| Macroadenoma | 32 | 6 | 26 | |
| Tumor character | 0.027 | |||
| Soft or fragile | 24 | 11 | 13 | |
| Hard or elastic | 14 | 1 | 13 | |
|
| ||||
| Perioperative CSF leakage | 0.012 | |||
| No | 23 | 11 | 12 | |
| Yes | 15 | 1 | 14 | |
| Diabetes insipidus | 0.481 | |||
| No | 15 | 6 | 9 | |
| Yes | 23 | 6 | 17 | |
| Residual tumor | 0.714 | |||
| No | 26 | 9 | 17 | |
| Yes | 12 | 3 | 9 | |
| Length of admission (days) | 11.9 ± 7.7 | 12.3 ± 11.2 | 11.8 ± 5.7 | 0.836 |
| Operation time (minutes) | 165.6 ± 61.8 | 169.8 ± 56.5 | 163.6 ± 65.1 | 0.780 |
Data are presented as number of patients or mean ± standard deviation.
CSF, cerebrospinal fluid.
Risk factors for residual tumors.
Residual tumor | |||
|---|---|---|---|
| Factor | Yes (n = 12) | No (n = 26) | |
| Tumor size (cm) | 3.0 ± 0.9 | 1.8 ± 0.7 | <0.001 |
| Adenoma type | 0.714 | ||
| Functional | 3 | 9 | |
| Nonfunctional | 9 | 17 | |
| Tumor character | 0.296 | ||
| Soft or fragile | 6 | 18 | |
| Hard or elastic | 6 | 8 | |
| Cavernous sinus invasion | 0.0001 | ||
| Yes | 7 | 0 | |
| No | 5 | 26 | |
Data are presented as number of patients or mean ± standard deviation.
Endocrine outcomes in patients with nonfunctional pituitary adenomas (n = 26).
Hormone levels | ||||||
|---|---|---|---|---|---|---|
| GH (ng/mL) | IGF-1 (ng/mL) | ACTH (pg/mL) | Cortisol (μg/dL) | PRL (ng/mL) | TSH (μIU/mL) | |
| Preoperative | 0.34 ± 0.43 | 124.1 ± 74.8 | 30.4 ± 20.6 | 13.4 ± 18.2 | 12.8 ± 15.6 | 1.31 ± 1.07 |
| Postoperative day 1 | 0.20 ± 0.22 | 88.5 ± 59.4 | 34.4 ± 16.2 | 16.2 ± 30.8[ | 30.8 ± 27.8[ | 1.22 ± 1.13 |
| Last follow-up | 0.05 ± 0.03[ | 45.8 ± 29.7[ | 28.3 ± 10.6 | 10.6 ± 7.2 | 7.2 ± 7.8[ | 1.52 ± 1.47 |
aStatistically significant (P < 0.05) in comparison of postoperative day 1 and last follow-up versus preoperative values.
Abbreviations: GH, growth hormone; IGF-1, insulin-like growth factor-1; PRL, prolactin; TSH, thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone.
Figure 2.Treatment strategies for residual pituitary tumors.